Valeant Pharmaceuticals International, Inc. (NYSE:VRX) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) gained 2.41 Percent and closed its previous trading session at $22.08. The stock traded with the average Volume of 10.03 Million at the end of last session.
The company reported its last earnings Actual EPS of $0.98/share. While, the analyst predicted that the company could provide an EPS of $0.97/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 1 Percent.
Sell side analysts plays vital role in buying and selling a stock where 4 analysts rated Valeant Pharmaceuticals International, Inc. (NYSE:VRX) as Buy, 0 analysts given Outperform signal, 4 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 18.75% where SMA50 and SMA200 are 29.6% and 32.72% respectively.
The company shows its Return on Assets (ROA) value of -2.4%. The Return on Equity (ROE) value stands at -18.8%. While it’s Return on Investment (ROI) value is 9.8%.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) currently has a Weekly Volatility of 3.84% percent while its Monthly Volatility is at 3.87% percent. While talking about Performance of the Stock, Valeant Pharmaceuticals International, Inc. currently has a Weekly performance of 9.04%, monthly performance percentage is 28.15 percent, Quarterly performance is 20.2 percent, 6 months performance shows a percent value of 51.23% and Yearly Performance is 56.82 percent.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.